|Referral date||01 June 2010|
|Closing date for invited submissions / evidence submission:||15 February 2013|
|1st appraisal committee meeting:||TBC|
|2nd appraisal committee meeting||TBC|
|Communications manager:||Alice Law|
|Executive Lead:||Andrew Dillon|
|Project manager:||Kate Moore|
|Technical Lead:||Grace Jennings|
|Manufacturers/sponsors||Arena Pharmaceuticals (lorcaserin hydrochloride)|
|Others||Department of Health|
|Staffordshire PCT Cluster|
|Welsh Assembly Government|
|National Obesity Forum|
|Professional groups||Association of British Clinical Diabetologists|
|National Diabetes Nurse Consultant Group|
|Royal College of Nursing|
|Royal College of Pathologists|
|Royal College of Physicians|
|The Obesity Management Association|
|Associated guideline groups||None|
|Associated public health groups||None|
|Comparator manufacturers||GlaxoSmithKline (orlistat) (confidentiality agreement not signed, not participating)|
|Roche Products (orlistat)|
|Evidence Review Group||National Institute for Health Research Health Technology Assessment Programme|
|School of Health & Related Research Sheffield (ScHARR)|
|General||Commissioning Support Appraisals Services|
|Department of Health,Social Services and Public Safety for Northern Ireland|
|Healthcare Improvement Scotland|
|Medicines and Healthcare products Regulatory Agency|
|22 May 2013||
NICE has been informed by the sponsor, Arena Pharmaceuticals, that they have withdrawn their licensing application for the above indication. The company is currently evaluating the best approach for submitting at a later date. Therefore this topic has now been suspended. We will continue to monitor any development and update you if the situation changes.
|03 May 2013||
Following an update on the regulatory status of this technology from the manufacturer, the discussion of this appraisal at the Committee meeting on 30 May 2013 has been cancelled.
We will update you with more information in due course.
|23 July 2012||
Following on from advice received from the manufacturer, this appraisal has now been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early December 2012. The deadline for submissions is expected in approximately mid February 2013.
|02 November 2011||
Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid October 2012. The deadline for submissions is expected in approximately mid December 2012.
For further information on our processes and methods, please see our CHTE processes and methods manual